Theriva™ biologics to participate in the q1 investor summit virtual

Rockville, md., march 05, 2025 (globe newswire) -- theriva™ biologics (nyse american: tovx), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that steve shallcross, chief executive officer, and manel cascallo, phd., general director will present at the q1 investor summit virtual. theriva's management team will participate in 1x1 meetings.
TOVX Ratings Summary
TOVX Quant Ranking